Patents by Inventor Jan J. Melenhorst

Jan J. Melenhorst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CAR T CELL THERAPIES WITH ENHANCED EFFICACY
    Publication number: 20240076372
    Abstract: The invention provides methods for manufacturing optimized CAR T cell therapies and uses thereof. Specifically, the invention provides parameters that can be measured, e.g., evaluated, to manufacture CAR T cell therapies with optimized properties. The invention further provides methods of use in connection with said optimized CAR T cells.
    Type: Application
    Filed: March 6, 2023
    Publication date: March 7, 2024
    Inventors: Christopher Loren Nobles, Frederic Dixon Bushman, Joseph A. Fraietta, Simon Lacey, Jan J. Melenhorst, Carl H. June
  • Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
    Patent number: 11896614
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: February 13, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: David M. Barrett, Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Nathan Amar Singh, Zoe Zheng
  • METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS
    Publication number: 20230295296
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
    Type: Application
    Filed: January 31, 2023
    Publication date: September 21, 2023
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Zoe Zheng
  • Biomarkers predictive of cytokine release syndrome
    Patent number: 11747346
    Abstract: The present disclosure relates to the identification and use of biomarkers (e.g., analytes, analyte profiles, or markers (e.g., gene expression and/or protein expression profiles)) with clinical relevance to cytokine release syndrome (CRS).
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: September 5, 2023
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Alfred Garfall, Alex Ganetsky, Saar Gill, Simon Lacey, Jan J. Melenhorst, David Teachey, Eric Lancaster, Adam David Cohen, Pamela Shaw
  • CAR T CELL THERAPIES WITH ENHANCED EFFICACY
    Publication number: 20230139800
    Abstract: The invention provides compositions and methods improved CAR T cell therapies. Specifically, the invention provides cells with reduced Tet, e.g., Tet2 function or expression, and methods of use therefore. The invention further provides Tet2 inhibitors and methods of use therefore in connection with CAR T cells.
    Type: Application
    Filed: September 20, 2022
    Publication date: May 4, 2023
    Inventors: Gregory Motz, Frederic Dixon Bushman, Joseph A. Fraietta, Carl H. June, Jan J. Melenhorst, Christopher Loren Nobles, Regina M. Young
  • BIOMARKERS FOR EVALUATING CAR-T CELLS TO PREDICT CLINICAL OUTCOME
    Publication number: 20210396739
    Abstract: The invention provides biomarkers, e.g, cancer biomarkers, and methods of using said biomarkers. Specifically, the invention provides biomarkers for use, e.g., in evaluating CAR-T cell therapies and predicting clinical outcome.
    Type: Application
    Filed: May 1, 2019
    Publication date: December 23, 2021
    Inventors: Iulian Pruteanu-Malinici, Jennifer Brogdon, Elena Orlando, Jan J. Melenhorst, Joseph A. Fraietta
  • METHODS FOR IMPROVING THE EFFICACY AND EXPANSION OF IMMUNE CELLS
    Publication number: 20210246423
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Application
    Filed: September 18, 2020
    Publication date: August 12, 2021
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Omkar U. Kawalekar, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Zoe Zheng
  • THERAPEUTIC REGIMENS FOR CHIMERIC ANTIGEN RECEPTOR (CAR)- EXPRESSING CELLS
    Publication number: 20210177896
    Abstract: The invention provides a method of treating an adult subject having a hematological cancer, comprising administering to the subject selected dosage regimens comprising a plurality of immune effector cells expressing a CAR molecule.
    Type: Application
    Filed: June 2, 2017
    Publication date: June 17, 2021
    Inventors: David L. Porter, Noelle Frey, Carl H. June, Simon Lacey, Fang Chen, Jan J. Melenhorst, Tetiana Taran, Karen Thudium Mueller, Patricia Wood, Yiyun Zhang
  • BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO CHIMERIC ANTIGEN RECEPTOR THERAPY AND USES THEREOF
    Publication number: 20210172020
    Abstract: Cancer biomarkers and methods of using them are disclosed.
    Type: Application
    Filed: August 6, 2020
    Publication date: June 10, 2021
    Inventors: Felipe Bedoya, Hans Bitter, Jennifer Brogdon, Corin Dorfmeier, Abhishek Garg, David Jonathan Glass, Joan Mannick, Jan J. Melenhorst, Michael C. Milone, Leon Murphy, Elena Orlando, Nicholas Wilcox
  • CAR T CELL THERAPIES WITH ENHANCED EFFICACY
    Publication number: 20210047405
    Abstract: The invention provides methods for manufacturing optimized CAR T cell therapies and uses thereof. Specifically, the invention provides parameters that can be measured, e.g., evaluated, to manufacture CAR T cell therapies with optimized properties. The invention further provides methods of use in connection with said optimized CART cells.
    Type: Application
    Filed: April 26, 2019
    Publication date: February 18, 2021
    Inventors: Christopher Loren Nobles, Frederic Dixon Bushman, Joseph A. Fraietta, Simon Lacey, Jan J. Melenhorst, Carl H. June
  • BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND USES THEREOF
    Publication number: 20200371091
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to a method of administering a BCMA-targeting chimeric antigen receptor (CAR) therapy and an additional therapeutic agent.
    Type: Application
    Filed: November 30, 2018
    Publication date: November 26, 2020
    Inventors: Iulian Pruteanu-Malinici, Keith Mansfield, Boris Engels, Jan J. Melenhorst, Adam David Cohen, Edward A. Stadtmauer, Alfred Garfall, Michael C. Milone, Joseph A. Fraietta
  • METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS
    Publication number: 20200370012
    Abstract: The disclosure provides methods of making CAR-expressing immune effector cells (e.g., T cells, or NK cells), and compositions and reaction mixtures comprising the same. The disclosure further provides methods of using said CAR-expressing immune effector cells.
    Type: Application
    Filed: October 25, 2018
    Publication date: November 26, 2020
    Inventors: Joseph A. Fraietta, Jan J. Melenhorst, Elena Orlando, Roderick O'Connor, Carl H. June
  • Methods for improving the efficacy and expansion of immune cells
    Patent number: 10829735
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: November 10, 2020
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Omkar U. Kawalekar, Bruce L. Levine, Jan J. Melenhorst, Michael Milone, Daniel J. Powell, Jr., Zoe Zheng
  • Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
    Patent number: 10774388
    Abstract: Cancer biomarkers and methods of using them are disclosed.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: September 15, 2020
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Felipe Bedoya, Hans Bitter, Jennifer Brogdon, Corin Dorfmeier, Abhishek Garg, David Jonathan Glass, Joan Mannick, Jan J. Melenhorst, Michael Milone, Leon Murphy, Elena Orlando, Nicholas Wilcox
  • BIOMARKERS AND CAR T CELL THERAPIES WITH ENHANCED EFFICACY
    Publication number: 20200087376
    Abstract: The invention provides compositions and methods improved CAR T cell therapies. Specifically, the invention provides cells with altered expression and/or function of one or more genes, e.g., associated with Tet2, and methods of use therefore. The invention further provides inhibitors of the one or more genes and methods of use therefore in connection with CAR T cells.
    Type: Application
    Filed: March 22, 2018
    Publication date: March 19, 2020
    Inventors: Joseph A. Fraietta, Jan J. Melenhorst
  • METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR - EXPRESSING CELLS
    Publication number: 20190292257
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
    Type: Application
    Filed: March 4, 2019
    Publication date: September 26, 2019
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, JR., Zoe Zheng
  • COMBINATION THERAPIES OF CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS
    Publication number: 20190151365
    Abstract: Provided are compositions and methods for treating diseases, e.g., cancers, e.g., diseases associated with expression of an antigen, e.g., CD 19, comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to the antigen, e.g., CD19, in combination with a PD-1 inhibitor.
    Type: Application
    Filed: July 28, 2017
    Publication date: May 23, 2019
    Applicants: Novartis AG, The Trustees of the University of Pennsylvania, The Trustees of the University of Pennsylvania
    Inventors: Oezlem Anak, Sanela Bilic, Jennifer Brogdon, John Scott Cameron, William Chou, Stephan Grupp, Danny Roland Howard, Jr., Randi Isaacs, Carl H. June, Simon Lacey, Shannon Maude, Jan J. Melenhorst, Stephen Shuster, Alfonso Quintas-Cardama
  • Methods of making chimeric antigen receptor-expressing cells
    Patent number: 10273300
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: April 30, 2019
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Zoe Zheng
  • CAR T CELL THERAPIES WITH ENHANCED EFFICACY
    Publication number: 20180258149
    Abstract: The invention provides compositions and methods improved CAR T cell therapies. Specifically, the invention provides cells with reduced Tet, e.g., Tet2 function or expression, and methods of use therefore. The invention further provides Tet2 inhibitors and methods of use therefore in connection with CAR T cells.
    Type: Application
    Filed: September 16, 2016
    Publication date: September 13, 2018
    Applicants: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Gregory Motz, Frederic Dixon Bushman, Joseph A. Fraietta, Carl H. June, Jan J. Melenhorst, Christopher Loren Nobles, Regina M. Young
  • BIOMARKERS PREDICTIVE OF CYTOKINE RELEASE SYNDROME
    Publication number: 20180252727
    Abstract: The present disclosure relates to the identification and use of biomarkers (e.g., analytes, analyte profiles, or markers (e.g., gene expression and/or protein expression profiles)) with clinical relevance to cytokine release syndrome (CRS).
    Type: Application
    Filed: September 2, 2016
    Publication date: September 6, 2018
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Alfred Garfall, Alex Ganetsky, Saar Gill, Simon Lacey, Jan J. Melenhorst, David Teachey